N/A N=253 Computerized Contraceptive Decision Aid
Contraception · Decision Making · Satisfaction
Primary: Decisional Conflict Scale Score — 15; 10; 0; 0 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=60 Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
Fabry Disease
Primary: Annualized Rate Of Change From Baseline To Month 18 In Measured Glomerular Filtration Rate — -4.35; -3.24 mL/min/1.73 m^2/year
Phase 2 N=60 R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Non-Hodgkin's Lymphoma
Primary: Response Rate — 57; 35 Participants
N/A N=63 Procedural Sedation And Analgesia in Children in the Emergency Department: The Role of Adjunct Therapies
Conscious Sedation
Primary: Sedation Medication Requirement — 1.58; 1.68; 1.42 mg/kg
Phase 2 N=49 Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
Opioid Abuse
Primary: Drug Liking at .5 Hours — 66.0; 74.7; 47.7; 40.9 score on a scale
Phase 2 N=44 Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users
Opioid-Related Disorders
Primary: Emax - Maximum Drug Liking — 54.5; 75.0; 72.1; 75.6 score on a scale
N/A N=60 XprESS Eustachian Tube Dilation Study
Eustachian Tube Dysfunction
Primary: Change From Baseline in Mean Overall ETDQ-7 Scores — -2.9; -0.6 units on a scale — p=<0.0001
N/A N=68 LLLT of Trophic Ulcers of Lower Extremities and Chronic Venous Insufficiency
Trophic Ulcers · Chronic Venous Insufficiency
Primary: Number of Participants With Trophic Ulcer Healing — 11; 28 Participants
Phase 1 N=117 PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients
Diabetes Mellitus, Type 2
Primary: Number of Participants Had Protocol-Defined Total Hypoglycemic Adverse Event (HAE) - Part A — 2; 2; 1; 1 participants
N/A N=266 Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention
Breast Cancer
Primary: Change in Absolute Breast Density — 65.53; 64.39; 65.08; 56.35 cm squared
N/A N=22 Effects of Two Supervised Training Programs for the Rehabilitation of Ankle Sprains
Ankle Sprains
Primary: Ankle Functional Stability, Via the Single-leg Hop for Distance Test — 65.6; 82.8; 100.3; 101.4 Centimeters
Phase 1 N=54 First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979
Healthy Subjects
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 0; 1; 0; 0 participants
Phase 2 N=334 A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006)
Hypercholesterolemia
Primary: Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -50.7; -40.6; -13.3; 4.6 Percentage Change
Phase 2 N=145 Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy
Arthritis, Rheumatoid
Primary: Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12…
Phase 2 N=12 Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men
Hypogonadism
Primary: Mean Serum Testosterone Cavg — 293; 246; 281; 385 ng/dL